RTTNews BiotechDoubao · 实盘不做把握 4/10不做原因:已被定价
北京时间·🕒 发布 15:25:01(美东 03:25)·⟳ 抓取 15:25:09 +8s·⚡ 决策 10-26 15:28:32 +3m23s·1.2 天前
百奥泰BAT8008(TROP2 ADC)联合BAT1308一线NSCLC的II期数据ESMO公布：ORR 61.2%、mPFS 12.42个月，数据积极但为单臂早期数据
利好于美东10月23日盘后（北京周六早）公开，百奥泰周一(10月26)已完成首个完整交易日，股价不涨反跌0.55%收18.01元，市场对单臂II期数据未予认可；同时科伦博泰sac-TMT III期更优数据在同一会议抬高TROP2 ADC+IO赛道门槛，本条催化无剩余可交易edge。
📄 原文RTTNews Biotech↗ 原文
Bio-Thera's BAT8008 Combination Shows 61.2% Response Rate In Phase 2 Lung Cancer Study
Bio-Thera Solutions, Ltd. (688177.SS) said Saturday it presented Phase 2 results at ESMO 2026 for BAT8008 in combinatio…
不做 百奥泰（688177.SH）
PRICE_IN/RISK_REWARD：利好周六随ESMO通稿公开，A股周一(10/26)首个交易窗口已收跌0.55%（会前20日已涨8.18%、上周五+4.44%有抢跑），市场对单臂II期、无对照、仅支持进一步评估的数据未给正反馈；同会科伦sac-TMT III期mPFS 15.0个月抬高赛道门槛，周二再买属于明牌追高，无正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BAT8008+BAT1308的II期NSCLC数据方向积极（ORR 61.2%、mPFS 12.42个月），但只是单臂早期、无对照、无注册里程碑，且被同会科伦博泰III期更优数据盖过；百奥泰周一首个交易窗口已收跌0.55%，利好已被消化甚至被负向解读，周二追多无正期望。
消息传播链
- 节点
- 节点
关键理由
- 数据本身阳性且安全性干净，为BAT8008肺癌线提供概念性验证，但不改变近期收入（公司当前营收主要来自格乐立、施瑞立等生物类似药，2026H1营收5.19亿元）
- 驱动基因阴性一线NSCLC是大适应症，但II期单臂数据距III期、申报或BD兑现仍有多个阶段，最早收入兑现需数年
主要风险
- 同会科伦/默沙东sac-TMT III期mPFS 15.0个月、HR 0.49，花旗明确称其raises the bar，BAT8008后续III期面临更高竞争标准
- ESMO常规摘要10月19日已放出、通稿周六发布，周一盘中已是明牌，见光死风险被周一实际收跌部分验证
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-24 · 影响 weakens
药物临床试验登记平台显示公司另一项试验CTR20242192为主动终止（非本次BAT8008肺癌试验，关联待核），且同赛道科伦III期数据更优；周一市场实际收跌0.55%构成对多头逻辑最直接的反证
检索:百奥泰 BAT8008 利空 终止 竞争 TROP2 ADC ESMO 原文 ↗ - 做多前查反向 · 来源 kb_search · 日期 2026-10-26 · 影响 weakens
高盛、花旗、摩根大通、伯恩斯坦ESMO点评均聚焦科伦博泰sac-TMT III期阳性结果，无任何券商在本批次点评中推荐百奥泰BAT8008，机构注意力被更强竞品吸走
检索:TROP2 ADC sac-TMT OptiTROP-Lung06 mPFS HR raises the bar
先例如何影响了这次决策
对本次决策的影响:先例缺失叠加周一已收跌的实际市场判决，直接支持不追多、AVOID
方向:未构建可用对齐先例
涨幅量级:无同市场同相位（ADC联合疗法ESMO II期读出后首个A股交易日）的锚干净先例，不用幅度数字定止盈止损
形态:本轮同会科伦博泰III期积极数据被高盛/伯恩斯坦预期周一大涨，可作ESMO TROP2 ADC数据交易的同主题背景，但非同标的、非同相位，不纳入定量先例
工具执行结果 · 成功 4 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 169 ms
{"result": "search_processed_events:agent query=`bat8008 联合 bat1308 一线肺癌 客观缓解率 无进展生存期 12.42 | bio-thera 688177 bat8008 trop2 adc nsclc phase 2 esmo 2026 | 百奥泰 bat8008 bat1308 esmo 非小细胞肺癌 ii期 orr 61.2%`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.1/72 小时、1643 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - web_search 成功 doubao_search · 1,852 ms
豆包搜索结果（原始查询:百奥泰 BAT8008 BAT1308 ESMO 2026 非小细胞肺癌 II期；API SearchType:web） - stock_quote 降级 stock_tools HTTP · 419 ms
{ - kb_search 成功 stock_tools HTTP · 289 ms
{
原文全文
展开原文 · 1,950 字
Bio-Thera Solutions, Ltd. (688177.SS) said Saturday it presented Phase 2 results at ESMO 2026 for BAT8008 in combination with BAT1308 as a first-line treatment for non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) accounts for most lung cancer cases. Patients with advanced disease lacking actionable genetic alterations continue to face treatment challenges.
BAT8008 is a TROP2-targeted antibody-drug conjugate designed to deliver a cancer-killing payload to tumor cells. While BAT1308 is an anti-PD-1 monoclonal antibody.
The Phase 2 study evaluated BAT8008 in combination with BAT1308 as a first-line treatment for advanced NSCLC. The reported mutation-negative population included 104 patients, with efficacy findings covering objective response rate and progression-free survival.
In this population, the combination achieved an objective response rate (ORR) of 61.2% and median progression-free survival of 12.42 months.
In the non-squamous subgroup, ORR was 65.2%, while median progression-free survival had not been reached.
The company said the combination showed a manageable safety profile consistent with the known safety characteristics of the individual drugs, with no new safety signals identified.
Bio-Thera said the findings support further evaluation of the combination in NSCLC.The data were presented at the European Society for Medical Oncology Congress (ESMO), being held October 23-27 in Madrid, Spain.
Bio-Thera shares are trading down 0.55% at CNY 18.01 on the Shanghai Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
Non-small cell lung cancer (NSCLC) accounts for most lung cancer cases. Patients with advanced disease lacking actionable genetic alterations continue to face treatment challenges.
BAT8008 is a TROP2-targeted antibody-drug conjugate designed to deliver a cancer-killing payload to tumor cells. While BAT1308 is an anti-PD-1 monoclonal antibody.
The Phase 2 study evaluated BAT8008 in combination with BAT1308 as a first-line treatment for advanced NSCLC. The reported mutation-negative population included 104 patients, with efficacy findings covering objective response rate and progression-free survival.
In this population, the combination achieved an objective response rate (ORR) of 61.2% and median progression-free survival of 12.42 months.
In the non-squamous subgroup, ORR was 65.2%, while median progression-free survival had not been reached.
The company said the combination showed a manageable safety profile consistent with the known safety characteristics of the individual drugs, with no new safety signals identified.
Bio-Thera said the findings support further evaluation of the combination in NSCLC.The data were presented at the European Society for Medical Oncology Congress (ESMO), being held October 23-27 in Madrid, Spain.
Bio-Thera shares are trading down 0.55% at CNY 18.01 on the Shanghai Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
c38bb0b5f6· 2026-10-26 15:28 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前